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1. Introduction
In this chapter the maturity of immune-therapy in cancer, with emphasis on melanoma will
be discussed.
The heterogeneity of melanoma tumour regarding primary and metastatic variants will be
argued. Therefore the mutational heterogeneity of this type of tumor triggers complex
immune-therapy approach. Notions such as Immune-therapy will be tackled, meaning targeting
immune elements like immune suppression and using immune drugs like monoclonal
antibodies against targets that can or not be immune elements. The chapter will end with the
importance of designing complex immune-therapies like abolishing the immune-suppression
and enhancing the specific anti-tumoral effect.
Physiologically, the immune system can recognize cells that display an aberrant proliferation
like neoplasia. The immune system is equipped with cells that can destroy cancer cells them
during their early development. Years ago, when the theory of immunoediting was initiated
[1], immunosurveillance was defined as a complex pathway that supervises and controls the
elimination of transformed self cells/tissue. When the immune system cannot properly control
these aberrantly proliferating cells, and the equilibrium is deregulated, tumour cells escape
and form a clinically significant tumoral tissue [2].
In cancer immune-therapy, several approaches that aim to start and sustain the immune
response and eventually elicit an immunological memory were lately tackled. The therapy
armentarium that started the “bumpy road” from bench to bedside comprises cancer vaccines,
adoptive T cell therapy, anti-tumor antibodies, immune checkpoint blockade and/or various
immune combinations. Some of the conclusions of the last Congress of SITC (Society for
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Immunotherapy of Cancer) is that combining these above mentioned immune approaches with
other immunomodulators (e.g. cytokines, cyclic dinucleotides) and/or indoleamine 2,3-
dioxygenase (IDO) inhibitors can increase the efficacy of immunotherapy [3] and hopefully
replace in the future routine approaches such as chemotherapy/radiotherapy.
Early diagnosed stages of melanoma are resolved mainly by surgery and large margin excision,
but for advanced stages, systemic therapies, whether chemotherapy, immune-therapy or
combined ones have had very low efficacy. Advanced melanoma remains a continuous clinical
provocation for the physicians who use therapeutical approaches with low response rates, un-
manageable toxicities, and reduced efficacy.
One of the main molecular hurdles in cutaneous melanoma is the heterogeneity of tumors.
A tumoral tissue has cells with different characteristics in terms of proliferation, invasive‐
ness and pheno/genotype. In melanoma, aggressiveness has a distinct cellular genotype and
in  the  tumor  dynamic  development,  cells  go  through  several  phenotype  switching  [4].
Specific genetic expression studies have identified more than 100 genes over-expressed in
cells with a higher proliferative capacity or in cells that were committed to invade tissues [5].
Recently, a study was published on single melanoma cells and the report shows that there are
114 genes expression that could distinguish the proliferative and invasive phenotype of cells.
Among these genes, regulatory networks were found along with genes that encode for
pluripotency factor (e.g. POUF51); all these genes were found associated with cell’s tumori‐
genic potential. Authors report that among the regulatory network genes, MITF (microphthal‐
mia-associated transcription factor) is one of the key players in the heterogeneous character of
tumour cells populations. Moreover, the heterogeneity of cells depends on the 2D or 3D status
of the cell cultures, thus TPBG (trophoblast glycoprotein) is expressed in a melanoma cell line,
501Mel, only in 3D cultures [4]. In the same way, in 1205Lu melanospheres, PI3K/AKT
(phosphatidylinositol 3' –kinase/protein kinase B) signaling pathway is enhanced [4], while
DAPK1 (death-associated protein kinase 1) expression is decreased in 501Mel experimental
tumors, finding that is in line with the hypermethylated gene promoter associated to melano‐
ma [6]. This study emphasizes that when transformed melanocytes start to organize in growing
tumors, the heterogeneity of the cellular populations’ increases, the tumoral tissue having
MITF-low/negative cells [4, 7]. In experimental tumour spheres, cells that grow on the exterior
layers have an active proliferation, while in the interior of the tumour, due to hypoxic
conditions, cells are arrested in the G1 phase [8]. The overall mechanism is that 3D growth
enhances tumour-initiating properties [9].
Cell’s heterogeneity is important from the immunological point of view. Tumour heteroge‐
neous tissues have different expression of tumor antigens, thus any type of therapy that
addresses only one tumour epitope is proned to have low efficacy. This is the rationale to
investigate  tumor  antigens  and  evaluate  the  patient’s  immune  responses  prior  to  any
immune-therapy [10].
Extensive studies performed by large groups of researchers and extended networks like
Melanoma Research Networks established in Europe, Canada, and New Zeeland have provided
seminal scientific information regarding melanoma’s immune biology. All these insights have
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led to an actual scientific leap by the development of the first immune-therapies that proved
efficacy in advanced melanoma treatment. Therefore drugs that aim intracellular pathways
such as mitogen-activated protein kinase (MAPK) pathway, or antibodies that aim CTLA4
(cytotoxic T lymphocyte-associated protein 4), or PD1/PD1-L (programmed cell death 1/
programmed cell death 1 ligand) have recently followed the bench to bedside path [11].
Building upon the early success of these therapies, trials involving new classes of drugs and
combinations of these drugs are underway [12].
Starting from 2011, metastatic melanoma beneficiated from four new approved drugs, all these
drugs proving in clinical trials the improvement of patient’s survival. From this four drugs,
one is a B-Raf enzyme inhibitor (vemurafenib), one is an inhibitor of the associated enzyme B-
Raf (dabrafenib), and one is a MEK inhibitor (trametinib); the only one that is an actual
immune-therapy, is an anti-CTLA-4 (ipilimumab) antibody [13]. Therefore searching new
efficacious immune-therapies in this disease is still an open subject of intense research.
This chapter summarizes the main achievements gathered in the last 3 years regarding
immune-therapy as the ultimate approach for melanoma treatment.
2. Reducing specific immune-suppression
Until recently, the approved therapy armentarium in advanced melanoma was comprising
only dacarbazine (DTIC), hydroxyurea, while the only approved immune agent was high-dose
interleukin-2 (IL-2) [14]. These drugs cannot provide satisfactory overall survival (OS) rates in
advanced stages. After searching various combination of immune-therapies, from vaccination
[15] to drugs that inhibit immune-signaling pathways [16], in 2011 FDA approved, ipilimumab
and vemurafenib, agents that significantly increased OS and long-term improvement in
advanced melanoma [17].
In this case, monoclonal antibodies (mAbs) as immune-therapy agents have the intrinsic role
to establish an antineoplastic action through stimulation of a specific immune response. This
action can be performed by inducing de novo primary response and/or by eliciting an already
existing antitumor action, but repressed in these patients.
The most advanced, in terms of positive research results, were the immune-related drugs that
abrogated the immune –suppression such as CTLA4 or PD-1. Other mAbs were designed to
aim toward stimulation of co-stimulatory receptors, molecules that are expressed by antigen
presenting cells (APC); the aimed molecules were CD40 or OX40 (member 4 tumor necrosis
factor receptor superfamily) or GITR (TNFRSF18), expressed on activated T lymphocytes.
Tremelimumab, also an anti CTLA4 mAb, is being evaluated in solid tumors. Nivolumab, an
anti PD-1 mAb is also in the evaluation phase. This year (2014) clinical trials assessing OX40-
and GITR-activating mAbs were initiated as well [18].
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2.1. Anti-CTLA-4 antibodies
Activated T lymphocytes express transiently CTLA-4 transmembrane protein, while on T
regulatory lymphocytes (Tregs) this protein is expressed constitutively. Two possible mecha‐
nisms are known accounting for CTLA-4 immune-suppressive effect. One of the mechanisms
is the competitive binding to B7-1 and B7-2 in the detriment of the normal binding to CD28,
delivering thus an immune-suppressive signal [19]. Actually CTLA-4 competes with the
binding of CD28 to B7, thus hindering a normal activation. The other possible mechanism is
that cells expressing CTLA-4, endocytose the appropriate ligands of other cells, as such, CD28
cannot trigger activation [20].
Overall in cancer research, drugs that aim B7 family can enhance the therapeutic panel and
thorough studies are further needed for elucidating these regulatory pathways [21].
The particular action of monoclonal anti-CTLA-4 antibody is to link to CTLA-4, blocking the
inhibitory immune-suppressive signal, T cell can perform thus its activation pathways,
proliferate while infiltrating the tumors, and in the end, set off tumour apoptosis. Designed to
bind to CTLA-4, ipilimumab was approved by FDA in 2011 for advanced melanoma [22] and
in the same year the European Commission issued a marketing authorization for ipilimumab
[23].This type of immune-drug aims to downregulate the inhibitory activity of T-lymphocytes
leading to the normal activation of T cells by allowing the binding of CD28 to B7, this costi‐
mulatory process participates to the main coupling of MHC (major histocompatibility
complex) that presents the tumour antigen to TCR (T cell receptor). Re-establishing these
physiological molecular interactions, T-cells can mount an efficient antitumor immune
response (Figure 1) [24]. CTLA-4 expressed on T cells is omnipresent and is not dependent
upon the tumour’s particularities, thus the drug’s action should not be dependent on tumor’s
characteristics.
EMA recommendation after analyzing the post-phase III results extended clinical trials [25,17]
is a dose of intravenously 3 mg/kg ipilimumab over a 90 min period, this procedure needs to
be repeated every 3 weeks; overall four doses should be administered [23]. If the patients are
treated in combination with DTIC it is recommended that a dose of 10 mg/kg should be used
[25,17].
The actual clinical results of using this immune-therapy showed that patients with advanced
melanoma increased their median OS to 10 months when compared to the 6 months OS in
gp100 melanoma vaccine. When comparing OS in patients treated with ipilimumab in
combination with DTIC, OS was 11 months, while DTIC monotherapy just 9 months.
As stated above ipilimumab’s action is not dependent on specific and individual tumor cell
mutations, hence it can be efficient in different patients and stages [26, 27]. The beneficial
clinical results regarding OS were registered as independent of various parameters such as
age, gender, stage and/or previous therapy regimens.
Investigating the patients survival curves it has been shown that there are groups surviving
more than 4 years [28], and that their clinical response was durable during the follow-up [29].
Durability is an important differentiating criterion when recommending first-line therapy with
immunomodulators in comparison to the duration obtained in kinase inhibitors treatment.
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As we are focusing on an immune therapy and as immune memory is a characteristic of this
process, it was a logic approach to see what the effects are when ipilimumab gets another round
of therapy. The National Comprehensive Cancer Network (NCCN) recommendation show
that ipilimumab re-treatment can be done when the first round induced intolerable toxicity
and/or for patients relapsing after the first therapy or proving at least 3 months stable disease
[30]. Adverse reaction during re-treatment are similar to those for the first approach (see below)
and no actual predisposition was noted regarding first encountered toxicity with the re-
treatment one. Authors report that retreatment with ipilimumab is a feasible therapy and,
currently a phase II trial (http://trialsunited.com/studies/NCT01709162) focuses on the
immune response parameters in ipilimumab re-treatment [31].
Non-cutaneous melanomas were also therapeutic targets for ipilimumab therapy. Thus, in an
Australian study published in 2014 over 100 patients were followed after ipilimumab therapy.
Median OS for mucosal and uveal melanoma patients was half of that registered in cutaneous
melanoma patients. This report underlines the severities of adverse effects, even death-related
to therapy cases, thus administration and follow-up by an experienced clinical team is
extremely necessary in this type of clinical trials [32].
Stage IV patients presenting brain metastasis were another therapy target group as blood-
brain barrier  is  permeable  to  activated T lymphocytes,  cells  capable  of  inducing a  local
immune response [33]. In a large study comprising over 800 patients with brain metasta‐
Figure 1. Main immune-suppression molecular mechanisms that can be overridden by therapeutical monoclonal anti‐
bodies targeting CTLA-4 and PD1.
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sis treated with ipilimumab, up to 25% survived at least 1 year, as the un-treated median
OS is only 5 months [34].
Adverse reactions in ipilimumab therapy are associated with hyper-immune reactions, but
these can be solved by the physician using additional classic therapies. Over 10% of patients
experienced gastrointestinal deregulations (e.g. diarrhea, nausea, vomiting, decreased
appetite and abdominal pain), rash, pruritus, fatigue. Side-effects are manageable by the
physician and, seldom, the severity can lead to treatment discontinuation (www.ema.euro‐
pa.eu). These immune-related adverse effects (irAEs) are mild to moderate toxicity and are
experienced by around 60% of the patients, while around 15% developed grade 3 or 4 toxicity
[25]. Endocrine system – related adverse effects were also reported in this therapy; in patients
group receiving ipilimumab, 8% have experienced hypophysitis and 6% hypothyroidism/
thyroiditis. Combined therapy, ipilimumab and nivolumab, induce in 22% of the patients
thyroiditis or hypothyroidism and in 9% hypophysitis. Authors report hormone replacement
as adjuvant therapy and immediate initiation of this therapy reverses symptoms [35]. If the
ipilimumab therapy is combined with vemurafenib, important hepatotoxicity was reported,
thus caution should be taken when combining immune-therapy with this B-Raf enzyme
inhibitor [36].
2.2. Anti-PD-1 or PD-1L antibodies
2.2.1. Nivolumab
In July 2014, the first human monoclonal antibody against programmed death receptor-1 was
announced as approved in Japan-Nivolumab [37]. As shown above in Figure 1, it targets a
negative regulatory molecule that sustains immunosuppression. After accomplishing phase I
and II clinical trials, around 25% of stage III and IV patients had a good clinical response when
2 mg/kg intravenous nivolumab was administered every 3 weeks. The clinical outcome was
very optimistic in this study, patients did not progress in their disease for a median of 172
days, and at the time of publication (July 2014) median OS was still not achieved.
Nivolumab displayed a good tolerability profile; grade 3 or 4 adverse effects were reported in
les than 18 % of patients, mainly an increased γ-glutamyl transferase [38].
Another group studying T lymphocyte interaction with tumour cell, interaction mediated by
PD-1 receptor linking to PD-L 1, has shown that in phase I/II studies this antibody can lead to
tumor regression and can enhance OS in various cancers including skin melanoma. Studying
antibodies that target PD-1 or PD-1L (e.g. nivolumab, MK-3475, pidilizumab, MPDL3280A,
BMS-936559, MEDI4736, MSB0010718C) the authors show that the positive clinical response
goes to a maximum of 50% response rate when antibodies against PD-1 combined with anti-
CTLA-4 were used. The clinical responses start early upon treatment and continue after the
treatment is finished [39].
Another study published in 2014 searched to evaluate the survival of patients upon discon‐
tinuation of the therapy. After enrolling over 100 patients with advanced melanoma, the
authors concluded that the median OS was 16.8 months [40].
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Melanoma patients along with other cancer diagnosed patients were treated with anti-PD-1
(nivolumab). This early-phase clinical trial published in 2014 aimed to elucidate the link
between PD-1, PD-L1, and PD-L2 expression, immune cell infiltration and the clinical efficacy
of this therapy. The degree of PD-L1 expression depicted on tumor cells was associated with
its receptor PD-1 expressed by lymphocytes. The other ligand of PD-1, PD-L2 corroborated
with PD-L1 expression. The expression of PD-L1 on the tumors was correlated with the clinical
efficacy of the anti-PD-1 therapy, and the found best correlation when compared to other
studied factors, such as PD-1 expression and/or TIL (tumor infiltrating lymphocytes). The
study concludes that, when achieving maximum efficacy with novilumab, tumor PD-L1
expression is the base of anti-PD-1 therapeutical blockade [41].
In 2013, results from phase I clinical trials, of nivolumab and MK-3475 (anti-PD-1 and anti-PD-
L1 antibodies) were released. For MK-3475 an objective response of 38 % with only 13 % of the
patients reporting grade 3/4 toxicities was shown [42]. These results were probably the ground
for further approval (see below).
Phase III clinical trails are on-going and, it seems that PD-1-PD-L1 triggers a sequence of
intracellular signaling that brings important clinical benefits [43].
Adverse effects in this type of therapy are of low grade, the physician can impose a good patient
management [39] and long-term safety is acceptable [40].
2.2.2. Pembrolizumab
In September 2014, FDA granted accelerated approval to pembrolizumab (formerly known as
MK-3475), an antibody targeting PD-1, to be used following ipilimumab therapy. A recently
published report showed the efficacy and safety results of this antibody at two doses (2
mg/kg and 10 mg/kg) given every 21 days. The enrolled patients that received the therapy
were refractory to ipilimumab therapy. Similar safety profiles were reported whether patients
were treated with 2 mg/kg or 10 mg/kg and authors show that no drug-related deaths were
registered [44]. Another published study had similar results with the difference that the
response rate between patients with or without prior ipilimumab treatment were not statisti‐
cally different. Positive clinical outcome was registered with the overall median progression-
free survival exceeding 7 months. Patients with advanced melanoma, prior refractory to
ipilimumab, proved in this study a high rate of tumor regression [45].
Drug-related adverse effects were fatigue in one third of the patients and around 20% of them
experienced pruritus and rash. Grade 3 fatigue was the single drug-related grade 3 to 4 adverse
effect in 3% of the patients [44].
The positive results in a difficult to manage patients, like the ones refractory to ipilimumab,
probably accelerated this drug authorization with two months ahead of its planned approval
and the clinical study is still on going [46].
After ipilimumab approval, finding another antibody that could be used as immune-therapy
for blocking an immune checkpoint like PD-1 and PD-1L gained an intense research frenzy in
the last years.Therapeutical approaches that use immunomodulatory drugs have completely
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different mode of action in comparison to the well-known chemotherapeutical procedures.
From this point of view investigating the intimate mechanisms that underlie their effect is of
outmost importance because it can reveal new signaling molecules, future to be drug targets.
Moreover biomarkers that can clinically predict the patient response could optimize the
approach and personalize the immune-therapy [47].
2.3. Biomarkers for clinical benefit prediction
In the last couple of years there is a less abundant literature focusing on predictive and/or
prognostic biomarkers in the immune-therapy of cutaneous melanoma. Biomarkers that were
published lately range from classic serum LDH, to membrane molecules and circulating cells
without any clear-cut biomarker that could predict the immune-therapy efficacy.
In the last year researchers were focusing on biomarkers that can predict immune-therapy with
ipilimumab outcome. Thus some studies show that ipilimumab therapy was correlated with
an increase in peripheral blood absolute lymphocyte count when patients had a good clinical
outcome in terms of OS. More specifically OS was 11.9 months for patients that had more than
1,000 lymphocyte count / μL peripheral blood in comparison to OS of 1.4 months in patients
with lower counts [48, 49]. These results were confirmed this year when increased absolute
lymphocyte count was associated with increased progression free survival (PFS) but not with
OS. Any other parameters including classic serum LDH did not relate to OS or PFS [32].
Another cell biomarker, forkhead box P3 (FoxP3) expressed by T-regs, was correlated with
positive clinical outcome in advanced melanoma patients [50].
Correlations were investigated regarding circulatory myeloid-derived suppressor cells (MDSC)
in treated patients. Authors report that circulatory MDSC with Lin(-) CD14(+) HLA-DR(-)
phenotype are increased in patients compared to normal. After surgically removing the tumour
and subjecting patients’ to ipilimumab treatment, this immune parameter did not change. Then
again, an interesting finding was that patients could be stratified in the ipilimumab-respond‐
ers and non-responders based on the lower and respectively higher concentration of circulato‐
ry MDSC, thus pinpointing these cells as possible predictive markers of response to ipilimumab.
This candidate immune-marker did not correlate with baseline serum LDH, but showed higher
values in severe metastasis compared to localized metastasis to skin and/or to lymph nodes [51].
As to the possible efficacy biomarkers for nivolumab therapy, in a phase I clinical trial, stage
III or IV patients were followed after this therapy by several biomarkers evaluation. This recent
study reports that high circulatory T lymphocytes with NY-ESO-1 and MART-1-specific
CD8(+) phenotype are associated with disease progression. After therapy, increased circula‐
tory Tregs and decreased antigen-specific T cells are the two immune biomarkers that were
found associated with disease progression. The expression of PD-L1 on the tumor did not
correlate with the clinical response [52].
2.4. Animal models studying immune-therapy mechanisms
There are few studies focusing on animal models that bring new data regarding the intimate
cellular mechanisms in immune-therapy. Having in mind the fact that these recent immune-
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therapies are limited to certain groups of patients, the published animal models searched for
the resistance mechanisms that could hinder this therapy.
In 2013, the role of IDO upon an experimental anti CTLA-4 blockade was shown. Authors used
IDO knockout mice and showed that, upon treatment with anti-CTLA-4 antibody, B16
melanoma was growing more slowly and that, the animals’ overall survival increased
compared to normal mice expressing IDO. The mechanisms were similar when the animal
model was treated with anti PD-1/ anti-PD-L1 and GITR. The authors show in this animal
model that CTLA-4 and IDO inhibitors converge and that the inhibitory role of IDO can be the
background mechanisms accounting for the resistance to anti-CTLA-4 therapy. Moreover, the
process is T lymphocyte dependent and, if this resistance is overridden, effector T cells are
found increased in tumour infiltration, the effector-to-regulatory T cell ratio increases as well
[53]. The molecular mechanisms of IDO expression are intimately related to the immune
response. Several years ago it was reported that IDO expression is controlled by T activated
lymphocytes through their secreted cytokines. IL-13 can repress the induction of IDO mediated
by IFN-gamma [54]. Regarding possible emerging therapies, authors report that fludarabine
that hinders the up-regulation of IDO in a T lymphocytes dependent manner, can be tested as
a pre-treatment drug for melanoma patients. These patients can receive afterwards immuno‐
therapies that would have been less efficient when IDO was over-expressed [55].
Using animal models, new emerging therapies can be discovered, overriding the resistance to
immune-therapies in certain patients groups.
3. Dendritic cells pulsed with specific antigens as inductors of specific
immune-response
Treatment paradigms aim to include naturally occurring dendritic cells subsets in a single
vaccine. The studies that are in the pre-clinical phases show synergistic effects between various
antigen-presenting cells. We will present different types of methodologies to pulse dendritic
cells, starting with mere cultivation of dendritic cells in total tumour lysates and ending with
newer technologies such as electroporation mRNA-pulsed dendritic cells. Recently, the first
clinical trials released their results and showed increased survival rates and broader anti-
cancer immune responses. These new clinical findings will be presented.
In just a short period of time, the cancer immunotherapy field has gained new combatants
through sipuleucel-T FDA approval, first DC immunovaccine for metastatic prostate cancer
patients, followed closely by ipilimumab, an antibody specific to CTLA-4 as major target in
metastatic melanoma [56]. Due to its clear tumor immunogenicity, melanoma treatment could
be handled from an immunotherapeutic viewpoint. However, an important issue in melanoma
immunovaccine success is the highly heterogeneous composition of antigens expressed within
tumor site along with different genetic patterns of melanoma patients [57]. Deciphering this
complex (intra)tumor heterogeneity of melanoma is directly linked to the possibility for clearly
identifying, targeting and manageing drug-resistant cell subpopulations from the tumour site
[58]. The genetic profile of melanoma patient is one of the foremost rationales for an autologous
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whole cell vaccine acting more efficiently in treating the micrometastasis than would an
allogeneic designed one.
Revisiting the melanoma vaccines, it was pointed out that a preponderant cytokine-driven
therapy activates a robust antitumoral T-cell mediated response representing a class of
individualized auto-vaccination formula, surmounting thus the melanoma intratumoral
heterogeneity [57]. Assembling a cancer vaccine aims to activate a specific anti-tumor immune
response and/or to better access the tumor-associated antigens. In cutaneous melanoma, the
pattern of tumor specific and tumor associated antigens is both large and heterogeneous,
making melanoma immunogenicity exploitable in therapeutic approaches. Therefore, the
plenty of discovered or yet hidden melanoma tumor antigens could open the way for vacci‐
nation of patients groups with the same vaccine type [59]. Being explored with synthetic
peptides, whole tumor cells, cellular lysates or autologous immunovaccine, dendritic cells
(DCs) take advantages in treatment or even in prevention approaches of cancer [60].
Dendritic cell in melanoma immunotherapy undergo a sequential number of actions. Thus,
loading DCs with a tumor antigen and a specific adjuvant will induce the maturation state
which involves antigens processing by proteasomal degradation and presenting the resulted
peptides to T cells via MHC complex to stimulate further CD4+ cells, CD8+ cells as well as
phagocytes and NK cells or, in certain activation conditions, induce Tregs that hamper
antitumor responses [61].
3.1. Dendritic cells subsets
In malignant skin, the principal subsets of DC responsible for Ag-specific T cell immune response
comprise epidermal (Langerhans cells) and dermal cell populations. The primary tumor site and
the sentinel  lymph nodes endure the immune-suppression generated by melanoma,  this
immune site being the field where T cells should start the fight against melanoma while being
armed by activated DC to engender anti-melanoma immunity [62]. As in case of tumor associated
macrophages, under the influence of tumor milieu DC are versatile players which could become
tumor-associated DC enhancing Immune-suppression by sustaining T cell regulatory activity
[63] (Table 1). Upon electrochemotherapy of tumor cells, for example, a relatively new approach
to deliver better an antitumor drug, melanoma inflammatory infiltrate contains beside dermal
DC, plasmacytoid DC cells for capturing tumor antigens to further elicit, along with dermal and
Langerhans cells, a T cell antitumor response [64].
DCs subsets Uptake receptors evaluated for immunotherapy of DC
Antigen uptake receptors Unique receptors TLR receptors
LC/dermal DC FcR; DEC205; CD40; DCIR Langerin TLR-3
pDC FcR; DEC205; CD40; DCIR CD303; CD123; BDCA-2 TLR-7; TLR-9 specific to pDC
MoDC FcR; DEC205; CD11c; CD40; DCIRDC-SIGN; MR TLR-4; 8; 3; 7.
Table 1. DCs subsets and receptors for immunovaccine (LC – Langerhans cell; pDC - plasmacytoid-derived DC; MoDC
– monocyte-derived DC; DEC205 – C-type lectin receptor on DC; BDCA-2 – blood dendritic cell antigen, specific to
pDC subset; DCIR - dendritic cell immunoreceptor; DC-SIGN - dendritic cell specific ICAM-3 grabbing non-integrin;
MR – mannose receptor; TLR – toll-like receptor )
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3.2. Exploring dendritic cells in melanoma immunovaccine
As skin is an abundant cellular immune network and hence an accessible portal for thera‐
peutical approaches, DC cells remain an attractive target in melanoma therapy both as ex-
vivo-generated or in-vivo-DC-targeting immunovaccine blueprint [65]. Peripheral blood and
Langerhans cells are the main sources for DCs immunotherapy. Langerhans cells and mono‐
cyte-derived DCs elicit immune responses in comparable levels although the cytokine
stimulation conditions are different. The initial therapeutical attempts with DCs vaccination
was based on ex-vivo generated monocyte-derived DC pulsed with tumor lysates, peptide or
tumor antigens which led to a tumor regression rate of 3-7%, having also a lower toxicity
compared with standard therapeutical procedures [66]. In melanoma, DC derived from CD34+
progenitors prove better results compared with monocyte-DC vaccine in spite of the known
heterogeneity of tumor antigens [10].
3.2.1. Loading DC with tumor associated-antigens
Loading effector immune cells with antigenic peptides or a whole tumor-associated antigen
(TAA) was initially designed as an immune vaccination system with T lymphocytes via MHC
molecules recognition. Due to possible issues related to molecule stability and/or delivery
route, resulting in an ineffective antigen presentation, these approaches could fail in clinic due
to a low response rate in patients. Using DC as tool for intracellular delivery of such tumor
antigenic peptides, the process of antigen presentation to T cells could be improved [67].
Moreover, the Th1/Th2 balance could be regulated by such modified DC. Therefore, DCs
loaded with MART-126-35 melanoma peptide were used in combination with anti-CTLA4
monoclonal antibody (tremelimumab) in advanced melanoma patients. Upon therapy, high
levels of pro-inflammatory Th1 invariant natural killer T cells (iNKT) CD8(+) was associated
with positive clinical responses, indicating that antitumor T cell activity could be immuno‐
modulated via iNKT cells by peptide-pulsed DCs [68]. In another recent study, high-risk stage
III melanoma patients with lymph node resection were vaccinated with DC loaded with MHC
I melanoma peptides respective to the patient’s haplotype. The peptide pulsed DCs were well
tolerated and elicited immune specific responses to melanoma antigens or/and IFN-γ-
producing CD8+ cell response to melanoma peptides in 15 of 22 patients. The three-year overall
survival rate was 68.2% vs. 25.7% in the control patients group [69].
Monocyte-derived DCs could be loaded in different conditions with a mixture of peptides,
tumor lysates or even with a single tumor peptide such as from Mage-3A1. For 8 of 11 patients
enrolled in the study it was registered an increase of Mage-3A1-specific (CD8+) T cells, with
regression of a few metastases for 6 advanced melanoma patients; a lack of Mage 3A1
expression was observed in some non-regressed areas of melanoma [70]. Even immature DCs
could be exploited in vaccination, thus DCs generated from CD34+ progenitor cells were
cytokines-stimulated and pulsed in vitro with a pool of melanoma derived peptides [71].
Engineered DCs loaded with peptides or antigens could be delivered by lymphatic nodes
or intradermally; the last type being the optimum method for generating T cell antitumor
immunity [72].
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3.2.2. DC electroporation with mRNA
Cellular electroporation is a transfection method to efficiently introduce mRNA encoding for
a certain biomolecule in order to express at high level that specific antigen. A main advantage
of mRNA transfection is the prolongation of the exposure and an accurate antigens processing.
This approach was translated for DCs as a promising opportunity to facilitate access to tumor
antigens and thus priming the T cell specific antitumor melanoma response, being applicable
even in advanced stages of melanoma [73].
In the last few years, mRNA was proposed as an innovative vehicle for antigen delivery
appropriate for cancer vaccination purposes. DCs were evaluated as the most suitable immune
cells for mRNA transfection due to their professional quality in processing and presenting
antigens for inducing specific immune responses by T cells. mRNA as an antigen delivery tool
could generate a whole antigenic protein with all epitopes ready to be viewed by MHC
molecules; last but not least, the interest mRNA molecule could be produced in large quantities
with high purity.
The successful use of ex vivo mRNA-modified DCs for melanoma immunotherapy rely on DCs
cellular subtype involved, the proper cellular activation and path of delivery [74]. The DCs
subtype electroporated with mRNA in cancer vaccination purposes accounts for vaccination
efficiency. pDCs cells loaded with melanoma antigenic peptides and further activated at
CD40L elicit T cytotoxic anti-melanoma responses [75]. The cellular activation method of DC
counts for CTL full activity and subsequently inhibition of Tregs. Engagement of TLR in DC
activation proves to be a good approach in immunovaccine. Moreover, transfection with
mRNA and activation of DC cells is the fundament of the TriMix mRNA set encoding for
CD40L, CD70 and active form of TLR4. Thus in one clinical study with TriMix-DCs intrader‐
mally administrated, the efficacy of procedure was registered by means of the skin infiltrating
CD8+ lymphocytes monitored by IL-12p70 as a marker of successful inoculation of the DC
product [76]. The delivery way of modified DCs was compared in several clinical studies. The
best way to target the lymph nodes in melanoma site by modified mRNA DCs is intradermic
inoculation associated with an increased number of T cells although intranodally delivery
reveal a higher number of DC. One recent study refers to DC electroporated with mRNA for
gp100/tyrosinase antigens and injected in regional lymph nodes of melanoma patients prior
to local surgery. The mRNA for electroporated melanoma antigen was immunohistochemi‐
cally detected in T cells populations from both the primary and the adjacent lymph node
concomitantly with a CD8+ T lymphocyte responses registered in 7 of 11 patients subjected to
immunovaccination [77]. Some promising results in terms of safety, feasibility and immuno‐
genic properties were obtained in patients with advanced cutaneous melanoma in a pilot study
were DC were co-electroporated with mRNA encoding for CD40L, TLR4 and CD70 as a
autologous TriMix-DC formula combined with IFN-α-2b sequential administration [76].
The foremost parameter to be monitored for immunovaccine efficacy is the induction or the
enhancement of melanoma anti-tumor immune response. Several technologies like ELISPOT
technique allows quantifying the precise number of active immune cells by counting antigen-
specific cells that secrete a particular anti-tumor cytokine e.g. IFN-γ [59]. Since 2006, clinical
studies with tumor mRNA transfected DCs administrated usually intradermic in patients with
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metastatic melanoma, detect an immunological T cell response with promising results at least
for disease stabilization. In addition, advanced melanoma patients were treated intradermic
with DCs simultaneously co-electroporated for 4 tumor antigens – Mage A3, Mage C2,
Tyrosinase and gp100/DC-LAMP followed by TriMix mRNA single or in combination with
additional therapy like IFNa-2b. In both clinical set-ups, the CD4/CD8 T cell responses were
enhanced [74].
Recently, a small study on seven melanoma patients involved DCs from peripheral blood
mononuclear cells pulsed with gp100 peptides and maturated further in vitro with a cocktail
of CD40L and INF-γ. It was noted a direct correlation between the clinical responses and levels
of IL-12 produced by modified DCs. The highest levels of IL-12 were registered in one patient
with complete remission. DCs from non-responding patients were unable to produce IL-12
without additional stimulation with TLR agonist, observation that induced a modification of
the in vitro maturation protocol and thus contributed to the improvement of the clinical
outcome [78].
4. Translating up-dated knowledge to clinics — Therapeutical future
scenery
There is a recent trend that advises as first therapy a BRAF inhibitor in advanced stages, because,
time-wise, these patients cannot build an effective immune response while in patients with
less advanced stages, immune-therapy will lead to a better outcome whether the patient
presents or not a BRAF mutation [79].
In the clinical management of melanoma it is certain that immune-therapy is one of the pillars.
Among this new therapeutical approaches, MEK inhibitors can overcome the resistance
induced by BRAF inhibitors [79, 80]. has shown in phase 3 clinical studies, an improved [81].
Combination of  these antibodies with the new anti-CTLA4 drug induces an astonishing
80%  or  more  tumor  regression  in  patients  (http://www.clinicaltrials.gov/show/
NCT01783938;  http://trialsunited.com/studies/NCT01024231/)  [82].  Newer  therapeutical
combination  of  ipilimumab  with  oncolytic  immunotherapy  with  GM-CSF-expressing
engineered herpes simplex virus, have shown in phase 3 clinical studies an improved OS
in advanced melanoma [83].
On-going studies seek to establish the clinical boundaries of NK adoptive transfer in melano‐
ma. Last year a study was published searching to rationalize the clinical trial framework [84]
as the prior published results of a pilot trial showed no tumor regression in spite of the
increased concentration of circulating autologous NK cells persistence [85].
Immunotherapy is the only therapeutical “light” that can increase OS in advanced melanomas.
Eliciting an efficient immune response takes a certain amount of time in order to have an
efficient anti-tumoral response, but as immunological memory is installed, the effect of immune-
therapy persists in the absence of further immune-treatment.
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We strongly believe, taking into account our experience in melanoma patients follow-up [86,
87] that immune-therapy is a major therapy weapon, increasing survival in advanced mela‐
nomas. The only draw-back is that, in order to develop its full efficacy, immune-therapy takes
time, and this time interval can be up to 2–4 months. Thus, an early diagnostic in the metastatic
stage would make a huge difference for a positive clinical outcome [88].
Besides imaging-based follow-up, immune parameters should complete the panel of investi‐
gation. New data regarding circulatory MDSC can enhance this panel and prospective clinical
trials should soon validate them. Resistance to immune-therapy, like IDO expression opens
new therapeutical avenues aiming at immune checkpoints and combining specific antibodies
with IDO inhibitors.
5. Conclusion
The immune system is still not fully explored in this type of skin cancer [89, 90], thus new
insights in tumour microenvironment and the involvement of innate immunity cells could
enhance the panel of new therapeutical targets.
Balancing antitumor efficacy and reconstitution of a proper functioning immune system are
processes aimed by immune-therapy in cutaneous melanoma. Owing to cutaneous melanoma
immunogenic outline, this disease treatment could be addressed from an immunotherapeutic
viewpoint. As we are facing the great success of having the first immune-therapy approved
drug in melanoma, there is an open research combat of targeting personalized/individual
antigens or undifferentiating antigens-stem-like to tackle the aggressive character of this
disease.
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